benzbromarone has been researched along with Chronic Kidney Diseases in 8 studies
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the benzbromarone group, kidney stones in one case increased in quantity." | 9.27 | Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. ( Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X, 2018) |
| "The objective of the study was to compare the relative effects of benzbromarone and allopurinol on the risk of developing chronic kidney disease in persons with asymptomatic hyperuricemia." | 8.31 | Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 7.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| " The aim of this study was to determine whether urate-lowering therapy with an XO inhibitor (febuxostat) and that with a uricosuric drug (benzbromarone) are comparable in slowing renal function decline in patients with CKD complicated with hypertension and hyperuricemia." | 5.69 | Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial. ( Arima, H; Funakoshi, R; Iseki, K; Ishida, A; Kinjyo, K; Kochi, M; Kohagura, K; Nakamura, T; Ohya, Y; Sakima, A; Satoh, A; Tana, T; Yamazato, M; Zamami, R, 2023) |
| "Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model." | 5.48 | Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. ( Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| " In the benzbromarone group, kidney stones in one case increased in quantity." | 5.27 | Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. ( Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X, 2018) |
| "The objective of the study was to compare the relative effects of benzbromarone and allopurinol on the risk of developing chronic kidney disease in persons with asymptomatic hyperuricemia." | 4.31 | Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 3.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| "Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model." | 1.48 | Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. ( Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Liu, J | 1 |
| Ma, L | 1 |
| Fu, P | 1 |
| Lai, SW | 1 |
| Liao, KF | 1 |
| Kuo, YH | 1 |
| Hwang, BF | 1 |
| Liu, CS | 1 |
| Kohagura, K | 1 |
| Satoh, A | 1 |
| Kochi, M | 1 |
| Nakamura, T | 1 |
| Zamami, R | 1 |
| Tana, T | 1 |
| Kinjyo, K | 1 |
| Funakoshi, R | 1 |
| Yamazato, M | 1 |
| Ishida, A | 1 |
| Sakima, A | 1 |
| Iseki, K | 1 |
| Arima, H | 1 |
| Ohya, Y | 1 |
| Chung, TT | 1 |
| Yu, KH | 1 |
| Kuo, CF | 1 |
| Luo, SF | 1 |
| Chiou, MJ | 1 |
| Lan, WC | 1 |
| Chen, JS | 1 |
| Tseng, WY | 1 |
| Hsieh, AH | 1 |
| Wang, LC | 1 |
| Chou, HW | 1 |
| Chiu, HT | 1 |
| Tsai, CW | 1 |
| Ting, IW | 1 |
| Yeh, HC | 1 |
| Huang, HC | 1 |
| Kuo, CC | 1 |
| Yu, H | 1 |
| Liu, X | 1 |
| Song, Y | 1 |
| Cheng, J | 1 |
| Bao, H | 1 |
| Qin, L | 1 |
| Zhou, X | 1 |
| Wang, L | 1 |
| Peng, A | 1 |
| Joo, K | 1 |
| Kwon, SR | 1 |
| Lim, MJ | 1 |
| Jung, KH | 1 |
| Joo, H | 1 |
| Park, W | 1 |
| Stamp, LK | 1 |
2 reviews available for benzbromarone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Pharmacological urate-lowering approaches in chronic kidney disease.
Topics: Biological Products; Drug Discovery; Flavonoids; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
2 trials available for benzbromarone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Topics: Benzbromarone; Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficien | 2023 |
Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Topics: Aged; Alpha-Globulins; Benzbromarone; Febuxostat; Female; Glomerular Filtration Rate; Hemoglobins; H | 2018 |
4 other studies available for benzbromarone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia.
Topics: Allopurinol; Benzbromarone; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Ren | 2023 |
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gou | 2019 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; | 2018 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes M | 2014 |